<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04921943</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-HS</org_study_id>
    <nct_id>NCT04921943</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline for MAC</brief_title>
  <official_title>Hypertonic Saline for Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NTM Info &amp; Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance&#xD;
      of mycobacteria in patients with M. avium complex lung infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MAC-HS study is an open label, randomized control trial of hypertonic saline in pulmonary&#xD;
      M. avium complex patients. Eligible patients who consent to participate will be randomized&#xD;
      1:1 to hypertonic saline or standard of care for 12 weeks. All patients in the treatment&#xD;
      group will take inhaled hypertonic saline twice daily for 12 weeks. Patients may continue&#xD;
      with other airway clearance methods (i.e. flutter, acapella valve, aerobika, postural&#xD;
      drainage, huff cough, percussion). Patients may also be treated with antibiotics targeted at&#xD;
      other pathogens if an exacerbation occurs. Patients may also be actively treated with inhaled&#xD;
      corticosteroid at the time of enrollment, with dosing adjustments during the trial&#xD;
      discouraged. Patients with disease progression at any time can be discontinued from the study&#xD;
      treatment and treated according to ATS/IDSA guidelines at the discretion of the primary&#xD;
      investigator. However, such patients will still complete the 12 week final visit, sputum&#xD;
      collection and AE assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Culture conversion</measure>
    <time_frame>12 weeks</time_frame>
    <description>At least two negative AFB cultures on different days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Semi-quantitative culture results</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate acid fast bacilli (AFB) smear results to see if there is a decreased mycobacterial load (i.e. AFB smear 4+ decreasing to 3+).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nontuberculous Mycobacterial Lung Disease</condition>
  <condition>Nontuberculous Mycobacterium Infection</condition>
  <arm_group>
    <arm_group_label>Hypertonic saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who randomize to the hypertonic saline arm will be prescribed a nebulizer device to nebulize hypertonic saline (7%) twice daily for 12 weeks. Hypertonic saline (3%) can be prescribed in the case of poor tolerability of the 7% solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who randomize to the standard of care arm will receive treatment for pulmonary MAC based on the approved ATS/IDSA guidelines. Changes to standard of care regimen may be made based on the investigator's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>Nebulizing with 7% hypertonic saline twice daily for 12 weeks.</description>
    <arm_group_label>Hypertonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 2 positive MAC sputum cultures in the last 12 months with at least one AFB&#xD;
             positive sputum obtained within 12 weeks prior to randomization&#xD;
&#xD;
          -  Meet American Thoracic Society (ATS)/ Infectious Disease Society of America (IDSA)&#xD;
             2007 pulmonary clinical disease criteria[1]&#xD;
&#xD;
          -  Age 18 and older&#xD;
&#xD;
          -  Diagnosis of Bronchiectasis and/or bronchiectatic findings evident on chest CT report&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who is unwilling or unable to provide consent or to comply with this&#xD;
             protocol&#xD;
&#xD;
          -  Cavitary NTM disease&#xD;
&#xD;
          -  Patients who are currently taking or within the prior 6 months received any of the&#xD;
             following: bedaquiline, or any component of ATS/IDSA multi-drug recommended therapy&#xD;
             (macrolide, ethambutol, rifampin) for MAC treatment&#xD;
&#xD;
          -  Diagnosis of HIV&#xD;
&#xD;
          -  Diagnosis of Cystic fibrosis&#xD;
&#xD;
          -  Active pulmonary tuberculosis, fungal, or nocardial disease requiring treatment at&#xD;
             screening&#xD;
&#xD;
          -  Current use of chronic systemic corticosteroids at doses of 15 mg/day for more than 3&#xD;
             months&#xD;
&#xD;
          -  Prior lung or other solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Siegel, PhD, MPH</last_name>
    <phone>503-494-1384</phone>
    <email>siegels@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haley Miller</last_name>
    <phone>503-346-1548</phone>
    <email>millehal@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Levinger</last_name>
      <phone>212-263-7951</phone>
      <email>Amy.Levinger@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Doreen Addrizzo-Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Siegel, PhD, MPH</last_name>
      <phone>503-494-1384</phone>
      <email>siegels@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Haley Miller</last_name>
      <phone>503-346-1548</phone>
      <email>millehal@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin L Winthrop, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M5G</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matty Mehrabi</last_name>
      <phone>416-603-5726</phone>
      <email>Matty.Mehrabi@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Theodore Marras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Kevin Winthrop</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

